Waldenström's macroglobulinemia risk factors: Difference between revisions
No edit summary |
Sara Mohsin (talk | contribs) No edit summary |
||
Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Common risk factors in the development of | Common [[risk factors]] in the [[development]] of [[lymphoplasmacytic lymphoma]] are [[monoclonal gammopathy of undetermined significance]], [[hereditary|heredity]], [[hepatitis C]] and other [[autoimmune disorders]], [[allergic]] [[conditions]] like [[hay fever]], multiple [[environmental factor]]<nowiki/>s, [[Human]] T-lymphotrophic [[virus]] type I or [[Epstein-Barr virus]], [[History and Physical examination|history]] of [[Helicobacter pylori infection]], [[History and Physical examination|history]] of [[immunosuppressant]] [[Drugs|drug therapy]] after an [[Organ transplant|organ transplant,]] [[diet]] [[Rich focus|rich]] in meat and [[Fat|fat and]] [[History and Physical examination|history]] of past [[Treatments|treatment]] for [[Hodgkin's lymphoma|Hodgkin lymphoma]]. | ||
==Risk Factors== | ==Risk Factors== | ||
Following are the common [[risk factors]] for the [[development]] of [[lymphoplasmacytic lymphoma]]:<ref name="RF">Waldenström's macroglobulinemia. American Cancer Society (2015)http://www.cancer.org/cancer/waldenstrommacroglobulinemia/detailedguide/waldenstrom-macroglobulinemia-risk-factors Accessed on November 6, 2015</ref><ref name="pmid16357024">{{cite journal| author=Treon SP, Hunter ZR, Aggarwal A, Ewen EP, Masota S, Lee C et al.| title=Characterization of familial Waldenstrom's macroglobulinemia. | journal=Ann Oncol | year= 2006 | volume= 17 | issue= 3 | pages= 488-94 | pmid=16357024 | doi=10.1093/annonc/mdj111 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16357024 }} </ref><ref name="pmid17785558">{{cite journal| author=McMaster ML, Csako G, Giambarresi TR, Vasquez L, Berg M, Saddlemire S et al.| title=Long-term evaluation of three multiple-case Waldenstrom macroglobulinemia families. | journal=Clin Cancer Res | year= 2007 | volume= 13 | issue= 17 | pages= 5063-9 | pmid=17785558 | doi=10.1158/1078-0432.CCR-07-0299 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17785558 }} </ref><ref name="pmid18703425">{{cite journal| author=Kristinsson SY, Björkholm M, Goldin LR, McMaster ML, Turesson I, Landgren O| title=Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden. | journal=Blood | year= 2008 | volume= 112 | issue= 8 | pages= 3052-6 | pmid=18703425 | doi=10.1182/blood-2008-06-162768 | pmc=2569164 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18703425 }} </ref><ref name="pmid18809818">{{cite journal| author=Koshiol J, Gridley G, Engels EA, McMaster ML, Landgren O| title=Chronic immune stimulation and subsequent Waldenström macroglobulinemia. | journal=Arch Intern Med | year= 2008 | volume= 168 | issue= 17 | pages= 1903-9 | pmid=18809818 | doi=10.1001/archinternmed.2008.4 | pmc=2670401 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18809818 }} </ref><ref name="pmid18387498">{{cite journal| author=de Sanjose S, Benavente Y, Vajdic CM, Engels EA, Morton LM, Bracci PM et al.| title=Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. | journal=Clin Gastroenterol Hepatol | year= 2008 | volume= 6 | issue= 4 | pages= 451-8 | pmid=18387498 | doi=10.1016/j.cgh.2008.02.011 | pmc=3962672 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18387498 }} </ref><ref name="pmid20181958">{{cite journal| author=Kristinsson SY, Koshiol J, Björkholm M, Goldin LR, McMaster ML, Turesson I et al.| title=Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia. | journal=J Natl Cancer Inst | year= 2010 | volume= 102 | issue= 8 | pages= 557-67 | pmid=20181958 | doi=10.1093/jnci/djq043 | pmc=2857799 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20181958 }} </ref><ref name="pmid18263783">{{cite journal| author=Ekström Smedby K, Vajdic CM, Falster M, Engels EA, Martínez-Maza O, Turner J et al.| title=Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. | journal=Blood | year= 2008 | volume= 111 | issue= 8 | pages= 4029-38 | pmid=18263783 | doi=10.1182/blood-2007-10-119974 | pmc=2288717 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18263783 }} </ref><ref name="pmid16985251">{{cite journal| author=Landgren O, Engels EA, Pfeiffer RM, Gridley G, Mellemkjaer L, Olsen JH et al.| title=Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia. | journal=J Natl Cancer Inst | year= 2006 | volume= 98 | issue= 18 | pages= 1321-30 | pmid=16985251 | doi=10.1093/jnci/djj361 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16985251 }} </ref><ref name="pmid20308603">{{cite journal| author=Royer RH, Koshiol J, Giambarresi TR, Vasquez LG, Pfeiffer RM, McMaster ML| title=Differential characteristics of Waldenström macroglobulinemia according to patterns of familial aggregation. | journal=Blood | year= 2010 | volume= 115 | issue= 22 | pages= 4464-71 | pmid=20308603 | doi=10.1182/blood-2009-10-247973 | pmc=2881498 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20308603 }} </ref><ref name="pmid25174029">{{cite journal| author=Vajdic CM, Landgren O, McMaster ML, Slager SL, Brooks-Wilson A, Smith A et al.| title=Medical history, lifestyle, family history, and occupational risk factors for lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. | journal=J Natl Cancer Inst Monogr | year= 2014 | volume= 2014 | issue= 48 | pages= 87-97 | pmid=25174029 | doi=10.1093/jncimonographs/lgu002 | pmc=4155457 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25174029 }} </ref> | |||
* [[Heredity]] | {| class="wikitable" | ||
|+ | |||
! colspan="3" style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Risk factors for the development of lymphoplasmacytic lymphoma}} | |||
|- | |||
| colspan="2" |Pre-[[Existential therapy|existing]] '''[[Monoclonal gammopathy of undetermined significance]] ([[MGUS]])''' is the most common [[Risk factors|risk factor]], [[Association (statistics)|associated]] with 40 [[Timespan|times]] more [[likelihood]] of [[Development|developing]] [[lymphoplasmacytic lymphoma]]<ref name="RF" /> | |||
| rowspan="7" |'''Non-modifiable [[Risk factors|factors]]''' | |||
|- | |||
|'''[[Inherited]] [[Immune disorder|immune disorders]]''' | |||
| | |||
*[[Hypogammaglobulinemia]] | |||
*[[Wiskott-Aldrich syndrome]] | |||
|- | |||
|[[Heredity|'''Heredity''']]<ref name="pmid16357024" /><ref name="pmid17785558" /><ref name="pmid18703425" /> | |||
|[[Patients]] with [[lymphoplasmacytic lymphoma]] usually have a close/first-[[Degree (angle)|degree]] [[Relative frequency|relative]] with the [[disease]] or with a [[Related phenomena|related]] [[B-cell leukemia|B-cell disease]], such as [[MGUS]] or certain types of [[lymphoma]] or [[leukemia]] | |||
|- | |||
| colspan="2" |'''[[Age]]''' >50 [[Year|years]] | |||
|- | |||
| colspan="2" |'''Gender'''-[[Male]] | |||
|- | |||
| colspan="2" |'''[[Race]]'''-[[White (mutation)|White]] | |||
|- | |||
| rowspan="4" |[[Autoimmune Disease|'''Autoimmune Diseases''']]<ref name="pmid18703425" /><ref name="pmid18809818" /><ref name="pmid18387498" /><ref name="pmid20181958" /><ref name="pmid18263783" /><ref name="pmid16985251" /> | |||
|Personal and [[family history]] of [[autoimmune diseases]] with [[autoantibodies]] and [[Chronic (medical)|chronic]] [[immune]] stimulation [[Lead|leads]] to 2-3 fold higher [[RiskMetrics|risk]] of [[Development|developing]] LPL, especially elevated [[risks]] are [[Association (statistics)|associated]] with following: | |||
* [[ | *[[Sjogren syndrome]] | ||
** | *[[Autoimmune hemolytic anemia]] | ||
*[[Sarcoidosis]] | |||
*[[SLE]] | |||
*[[Rheumatoid arthritis]] | |||
*[[Psoriasis]] | |||
|- | |||
| | |||
*[[Chronic (medicine)|Chronic]] [[hepatitis C]] [[infection]] [[Lead|leads]] to an overall 20-30% increased [[RiskMetrics|risk]] for [[Development|developing]] [[Non-Hodgkin lymphoma|non-Hodgkin lymohoma]] and 3-fold increased [[RiskMetrics|risk]] for [[lymphoplasmacytic lymphoma]] | |||
| rowspan="10" |'''Modifiable''' '''[[Risk factors|factors]]''' | |||
|- | |||
| | |||
* [[Human Immunodeficiency Virus (HIV)|HIV]] | |||
|- | |||
| | |||
* [[Rickettsiosis]] | |||
|- | |||
|'''[[Allergic]] [[conditions]]''' | |||
|[[Hay fever]] is also known to be [[Association (statistics)|associated]] with increased [[RiskMetrics|risk]] of [[lymphoplasmacytic lymphoma]] | |||
|- | |||
| colspan="2" |'''[[Human]] T-lymphotrophic [[virus]] type I''' or '''[[Epstein Barr virus|Epstein-Barr virus]] [[infection]]''' | |||
|- | |||
|[[Environmental factor|'''Environmental factors''']]<ref name="pmid20308603" /><ref name="pmid25174029" /> | |||
|According to some recent [[Study design|studies]], exposure to following [[environmental factor]]<nowiki/>s seems to have an [[Association (statistics)|association]] with the [[development]] of LPL: | |||
* [[ | *[[Occupational Medicine|Occupational]] (Farming) | ||
** | *[[Pesticides]] | ||
***[[ | *[[Paint thinner|Paint]] | ||
** | *[[Rubber Vine|Rubber]] [[dyes]] | ||
*[[Benzene]] | |||
*[[Coal tar|Coal]] [[dust]] | |||
*Leather manufacturing | |||
*[[Wood]] [[dust]] | |||
*[[Organic solvents]] | |||
|- | |||
| colspan="2" |[[History and Physical examination|History]] of '''[[Helicobacter pylori infection]]''' | |||
|- | |||
| colspan="2" |[[History and Physical examination|History]] of '''[[immunosuppressant]] [[Drugs|drug therapy]]''' after an '''[[organ transplant]]''' | |||
|- | |||
| colspan="2" |'''[[Diet]]''' [[Rich focus|rich]] in '''meat''' and '''[[fat]]''' | |||
|- | |||
| colspan="2" |[[History and Physical examination|History]] of '''past [[Treatments|treatment]]''' for '''[[Hodgkin's lymphoma|Hodgkin lymphoma]]''' | |||
|} | |||
==References== | ==References== | ||
{{ | {{Reflist|2}} | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Blood]] | [[Category:Blood]] | ||
[[Category:Hematology]] | [[Category:Hematology]] |
Revision as of 21:07, 29 July 2019
Waldenström's macroglobulinemia Microchapters |
Differentiating Waldenström's macroglobulinemia from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Waldenström's macroglobulinemia risk factors On the Web |
American Roentgen Ray Society Images of Waldenström's macroglobulinemia risk factors |
Directions to Hospitals Treating Waldenström's macroglobulinemia |
Risk calculators and risk factors for Waldenström's macroglobulinemia risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2], Mirdula Sharma, MBBS [3], Roukoz A. Karam, M.D.[4]; Grammar Reviewer: Natalie Harpenau, B.S.[5]
Overview
Common risk factors in the development of lymphoplasmacytic lymphoma are monoclonal gammopathy of undetermined significance, heredity, hepatitis C and other autoimmune disorders, allergic conditions like hay fever, multiple environmental factors, Human T-lymphotrophic virus type I or Epstein-Barr virus, history of Helicobacter pylori infection, history of immunosuppressant drug therapy after an organ transplant, diet rich in meat and fat and history of past treatment for Hodgkin lymphoma.
Risk Factors
Following are the common risk factors for the development of lymphoplasmacytic lymphoma:[1][2][3][4][5][6][7][8][9][10][11]
References
- ↑ 1.0 1.1 Waldenström's macroglobulinemia. American Cancer Society (2015)http://www.cancer.org/cancer/waldenstrommacroglobulinemia/detailedguide/waldenstrom-macroglobulinemia-risk-factors Accessed on November 6, 2015
- ↑ 2.0 2.1 Treon SP, Hunter ZR, Aggarwal A, Ewen EP, Masota S, Lee C; et al. (2006). "Characterization of familial Waldenstrom's macroglobulinemia". Ann Oncol. 17 (3): 488–94. doi:10.1093/annonc/mdj111. PMID 16357024.
- ↑ 3.0 3.1 McMaster ML, Csako G, Giambarresi TR, Vasquez L, Berg M, Saddlemire S; et al. (2007). "Long-term evaluation of three multiple-case Waldenstrom macroglobulinemia families". Clin Cancer Res. 13 (17): 5063–9. doi:10.1158/1078-0432.CCR-07-0299. PMID 17785558.
- ↑ 4.0 4.1 4.2 Kristinsson SY, Björkholm M, Goldin LR, McMaster ML, Turesson I, Landgren O (2008). "Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden". Blood. 112 (8): 3052–6. doi:10.1182/blood-2008-06-162768. PMC 2569164. PMID 18703425.
- ↑ 5.0 5.1 Koshiol J, Gridley G, Engels EA, McMaster ML, Landgren O (2008). "Chronic immune stimulation and subsequent Waldenström macroglobulinemia". Arch Intern Med. 168 (17): 1903–9. doi:10.1001/archinternmed.2008.4. PMC 2670401. PMID 18809818.
- ↑ 6.0 6.1 de Sanjose S, Benavente Y, Vajdic CM, Engels EA, Morton LM, Bracci PM; et al. (2008). "Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium". Clin Gastroenterol Hepatol. 6 (4): 451–8. doi:10.1016/j.cgh.2008.02.011. PMC 3962672. PMID 18387498.
- ↑ 7.0 7.1 Kristinsson SY, Koshiol J, Björkholm M, Goldin LR, McMaster ML, Turesson I; et al. (2010). "Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia". J Natl Cancer Inst. 102 (8): 557–67. doi:10.1093/jnci/djq043. PMC 2857799. PMID 20181958.
- ↑ 8.0 8.1 Ekström Smedby K, Vajdic CM, Falster M, Engels EA, Martínez-Maza O, Turner J; et al. (2008). "Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium". Blood. 111 (8): 4029–38. doi:10.1182/blood-2007-10-119974. PMC 2288717. PMID 18263783.
- ↑ 9.0 9.1 Landgren O, Engels EA, Pfeiffer RM, Gridley G, Mellemkjaer L, Olsen JH; et al. (2006). "Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia". J Natl Cancer Inst. 98 (18): 1321–30. doi:10.1093/jnci/djj361. PMID 16985251.
- ↑ 10.0 10.1 Royer RH, Koshiol J, Giambarresi TR, Vasquez LG, Pfeiffer RM, McMaster ML (2010). "Differential characteristics of Waldenström macroglobulinemia according to patterns of familial aggregation". Blood. 115 (22): 4464–71. doi:10.1182/blood-2009-10-247973. PMC 2881498. PMID 20308603.
- ↑ 11.0 11.1 Vajdic CM, Landgren O, McMaster ML, Slager SL, Brooks-Wilson A, Smith A; et al. (2014). "Medical history, lifestyle, family history, and occupational risk factors for lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project". J Natl Cancer Inst Monogr. 2014 (48): 87–97. doi:10.1093/jncimonographs/lgu002. PMC 4155457. PMID 25174029.